Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA's 2012 Draft Guidance for Industry

Ähnliche Einträge

• FDA Commissioner Outlines New Plan to Increase Biosimilars by Balancing Innovation and Competition
  von: Koutnik-Fotopoulos, Eileen
  Veröffentlicht: (2018)
• FDA Readies New Guidance and User Fee Program for Biosimilars: Drug interchangeability and user fees are contentious issues the FDA must resolve. Is the FDA up to the task?
  von: BARLAS, STEPHEN
  Veröffentlicht: (2012)
• User Fees and Beyond — The FDA Safety and Innovation Act of 2012
  von: Kramer, Daniel B., et al.
  Veröffentlicht: (2012)
• New FDA Draft Guidance on Immunogenicity
  von: Parenky, Ashwin, et al.
  Veröffentlicht: (2014)
• FDA Guidance on Biosimilar Interchangeability Elicits Diverse Views: Current and Potential Marketers Complain About Too-High Hurdles
  von: Barlas, Stephen
  Veröffentlicht: (2017)